Search Results - "Kauschinger, Johanna"

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose by Jilg, Stefanie, Hauch, Richard T, Kauschinger, Johanna, Buschhorn, Lars, Odinius, Timo O, Dill, Veronika, Müller-Thomas, Catharina, Herold, Tobias, Prodinger, Peter M, Schmidt, Burkhard, Hempel, Dirk, Bassermann, Florian, Peschel, Christian, Götze, Katharina S, Höckendorf, Ulrike, Haferlach, Torsten, Jost, Philipp J

“…Patients with Myelodysplastic Syndromes (MDS) and secondary Acute Myeloid Leukemia (sAML) have a very poor prognosis after failure of hypomethylating agents…”
Get full text

RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells by Höckendorf, Ulrike, Yabal, Monica, Herold, Tobias, Munkhbaatar, Enkhtsetseg, Rott, Stephanie, Jilg, Stefanie, Kauschinger, Johanna, Magnani, Giovanni, Reisinger, Florian, Heuser, Michael, Kreipe, Hans, Sotlar, Karl, Engleitner, Thomas, Rad, Roland, Weichert, Wilko, Peschel, Christian, Ruland, Jürgen, Heikenwalder, Mathias, Spiekermann, Karsten, Slotta-Huspenina, Julia, Groß, Olaf, Jost, Philipp J.

“…Since acute myeloid leukemia (AML) is characterized by the blockade of hematopoietic differentiation and cell death, we interrogated RIPK3 signaling in AML…”
Get full text

Combination of 5-Azacytidine and ABT-199 Has a Synergistic Apoptotic Effect in High-Risk MDS/sAML after HMA Failure by Jilg, Stefanie, Kauschinger, Johanna, Reidel, Veronika, Müller-Thomas, Catharina, Hauch, Richard, Schauwecker, Johannes, Schmidt, Burkhard, Höckendorf, Ulrike, Peschel, Christian, Götze, Katharina, Jost, Philipp J.

“…Introduction: Myelodysplastic syndromes (MDS) are one of the most common haematological disorders of the older patient. Allogeneic stem cell stransplantation…”
Get full text

Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile by Reidel, Veronika, Kauschinger, Johanna, Hauch, Richard T, Müller-Thomas, Catharina, Nadarajah, Niroshan, Burgkart, Rainer, Schmidt, Burkhard, Hempel, Dirk, Jacob, Anne, Slotta-Huspenina, Julia, Höckendorf, Ulrike, Peschel, Christian, Kern, Wolfgang, Haferlach, Torsten, Götze, Katharina S, Jilg, Stefanie, Jost, Philipp J

“…Somatic mutations in genes such as , , or adversely affect the outcome of patients with myelodysplastic syndromes (MDS). Since selective BCL-2 inhibition is a…”
Get full text

Inhibition of PLK1 by capped‐dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis by Dill, Veronika, Kauschinger, Johanna, Hauch, Richard T., Buschhorn, Lars, Odinius, Timo O., Müller‐Thomas, Catharina, Mishra, Ritu, Kyncl, Michele C., Schmidt, Burkhard, Prodinger, Peter M., Hempel, Dirk, Bellos, Frauke, Höllein, Alexander, Kern, Wolfgang, Haferlach, Torsten, Slotta‐Huspenina, Julia, Bassermann, Florian, Peschel, Christian, Götze, Katharina S., Waizenegger, Irene C., Höckendorf, Ulrike, Jost, Philipp J., Jilg, Stefanie

“…Introduction Targeting the cell cycle machinery represents a rational therapeutic approach in myelodysplastic syndromes (MDS) and secondary acute myeloid…”
Get full text